IN2014MN02106A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02106A IN2014MN02106A IN2106MUN2014A IN2014MN02106A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A IN 2106MUN2014 A IN2106MUN2014 A IN 2106MUN2014A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- disclosed
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229930195695 Halichondrin Natural products 0.000 abstract 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 abstract 1
- 229960003649 eribulin Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618004P | 2012-03-30 | 2012-03-30 | |
| US201261647127P | 2012-05-15 | 2012-05-15 | |
| PCT/CA2013/050254 WO2013142999A1 (en) | 2012-03-30 | 2013-03-28 | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02106A true IN2014MN02106A (cs) | 2015-09-11 |
Family
ID=49258019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2106MUN2014 IN2014MN02106A (cs) | 2012-03-30 | 2013-03-28 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9278979B2 (cs) |
| EP (1) | EP2831082B1 (cs) |
| JP (1) | JP6531911B2 (cs) |
| CN (1) | CN104334562A (cs) |
| AU (1) | AU2013239290B2 (cs) |
| CA (1) | CA2868627C (cs) |
| IN (1) | IN2014MN02106A (cs) |
| WO (1) | WO2013142999A1 (cs) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE45324E1 (en) | 2004-06-03 | 2015-01-06 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
| MX2010003599A (es) | 2007-10-03 | 2010-09-10 | Eisai R&D Man Co Ltd | Intermediarios y metodos para la sintesis de analogos de halicondrina b. |
| SG10201500552PA (en) | 2010-01-26 | 2015-03-30 | Eisai R&D Man Co Ltd | Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs |
| CA2857385A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| CN104024237B (zh) | 2011-12-16 | 2016-02-24 | 阿方拉研究股份有限公司 | 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体 |
| IN2014MN01521A (cs) | 2011-12-29 | 2015-05-01 | Alphora Res Inc | |
| US9850254B2 (en) | 2013-07-03 | 2017-12-26 | Sandoz Ag | Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups |
| CN103483352A (zh) * | 2013-10-18 | 2014-01-01 | 李友香 | 抗肿瘤的药用原料药 |
| CN105683198B (zh) * | 2013-11-04 | 2019-03-12 | 卫材R&D管理有限公司 | 软海绵素b的类似物合成中有用的大环化反应和中间体 |
| MX370611B (es) | 2013-12-06 | 2019-12-18 | Eisai R&D Man Co Ltd | Metodos utiles en la sintesis de analogos de halicondrina b. |
| TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Ａｌｐｈｏｒａ研發股份有限公司 | （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物 |
| JP2017520586A (ja) | 2014-06-30 | 2017-07-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハリコンドリン類似体の合成およびその使用 |
| CN105713031B (zh) * | 2014-12-05 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种用于制备艾日布林的中间体及其制备方法 |
| US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| WO2016179607A1 (en) * | 2015-05-07 | 2016-11-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
| WO2017139664A1 (en) | 2016-02-12 | 2017-08-17 | Eisai & R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| WO2017203459A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| SG11201811671XA (en) | 2016-06-30 | 2019-01-30 | Eisai R&D Man Co Ltd | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| EP3544596A4 (en) | 2016-11-23 | 2020-10-07 | Dr. Reddy S Laboratories Limited | PROCESS FOR MANUFACTURING ERIBULIN AND INTERMEDIATE PRODUCTS THEREOF |
| CN108658956B (zh) * | 2017-03-28 | 2021-02-02 | 上海时莱生物技术有限公司 | 艾日布林中间体及其制备方法 |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| RS63755B1 (sr) | 2017-04-05 | 2022-12-30 | Harvard College | Makrociklično jedinjenje i njegova upotreba |
| CN108948064B (zh) * | 2017-05-17 | 2021-02-02 | 上海时莱生物技术有限公司 | 一种艾日布林中间体及其制备方法 |
| WO2018217894A1 (en) * | 2017-05-24 | 2018-11-29 | Eisai R&D Management Co., Ltd. | Fluorine-labelled halichondrin derivatives and related methods of synthesis |
| MX2020000142A (es) * | 2017-07-06 | 2020-07-22 | Harvard College | Sintesis de halicondrinas. |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
| EP3737673B1 (en) | 2018-01-03 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Process for preparing halichondrin macrolides and analogs thereof by a prins reaction, and intermediates of this process |
| IL279168B (en) | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | A process for the preparation of eribulin |
| CN114213429B (zh) * | 2021-12-22 | 2023-06-20 | 苏州正济药业有限公司 | 一种甲磺酸艾立布林杂质的制备方法 |
| IL322106A (en) * | 2023-01-17 | 2025-09-01 | Systimmune Inc | Eribulin drug conjugate |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338865A (en) | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| DE69423966T2 (de) | 1993-07-09 | 2000-11-16 | Laboratoire Theramex, Monaco | Neue strukturelle vitamin d derivate |
| HU227912B1 (en) * | 1998-06-17 | 2012-05-29 | Eisai R & D Man Co | Halichondrin analogs and methods of their use and preparation |
| US7001982B2 (en) | 2003-03-31 | 2006-02-21 | Council Of Scientific And Industrial Research | Non-natural C-linked carbo-β-peptides with robust secondary structures |
| USRE45324E1 (en) | 2004-06-03 | 2015-01-06 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
| US20060045846A1 (en) * | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| EP2274309B1 (en) * | 2008-04-04 | 2015-07-29 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
| CA2857385A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| CN104024237B (zh) | 2011-12-16 | 2016-02-24 | 阿方拉研究股份有限公司 | 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体 |
| IN2014MN01521A (cs) | 2011-12-29 | 2015-05-01 | Alphora Res Inc | |
| AR096238A1 (es) | 2013-05-15 | 2015-12-16 | Alphora Res Inc | Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo |
-
2013
- 2013-03-28 WO PCT/CA2013/050254 patent/WO2013142999A1/en active Application Filing
- 2013-03-28 CA CA2868627A patent/CA2868627C/en active Active
- 2013-03-28 US US14/389,439 patent/US9278979B2/en not_active Expired - Fee Related
- 2013-03-28 JP JP2015502027A patent/JP6531911B2/ja not_active Expired - Fee Related
- 2013-03-28 AU AU2013239290A patent/AU2013239290B2/en not_active Ceased
- 2013-03-28 EP EP13769493.1A patent/EP2831082B1/en not_active Not-in-force
- 2013-03-28 IN IN2106MUN2014 patent/IN2014MN02106A/en unknown
- 2013-03-28 CN CN201380028907.2A patent/CN104334562A/zh active Pending
-
2016
- 2016-02-04 US US15/015,161 patent/US9695187B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013142999A1 (en) | 2013-10-03 |
| EP2831082A4 (en) | 2016-01-06 |
| AU2013239290A1 (en) | 2014-10-30 |
| AU2013239290B2 (en) | 2017-08-03 |
| CA2868627A1 (en) | 2013-10-03 |
| EP2831082B1 (en) | 2019-02-20 |
| JP2015512897A (ja) | 2015-04-30 |
| US9278979B2 (en) | 2016-03-08 |
| JP6531911B2 (ja) | 2019-06-19 |
| CN104334562A (zh) | 2015-02-04 |
| EP2831082A1 (en) | 2015-02-04 |
| US9695187B2 (en) | 2017-07-04 |
| US20150065733A1 (en) | 2015-03-05 |
| US20160152631A1 (en) | 2016-06-02 |
| CA2868627C (en) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02106A (cs) | ||
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| IN2014MN01521A (cs) | ||
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| IN2014MN02598A (cs) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| MY175854A (en) | Novel quinolone derivatives | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| IN2014MN02459A (cs) | ||
| IN2014CN04530A (cs) | ||
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| MX2014007897A (es) | Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos. | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| IN2015DN01119A (cs) | ||
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| PH12016500394A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| IN2012DN02502A (cs) | ||
| MX390763B (es) | Compuestos de tetraciclina | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| IN2014CN04449A (cs) | ||
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |